Vifant (Penn Center for Innovation)
A medical mobile solutions development company
Monday, November 9, 2015
Embassy Suites, Chesterbrook, Pennsylvania (directions)
|
About
|
Vifant is committed to delivering innovative, cost-effective, mobile solutions for the early identification of vision impairment in verbal, non-verbal and pre-verbal patients as young as two months of age.
Early detection of vision problems improves treatment outcome, simplifies treatment and may prevent irreversible neurological damage and blindness. Accurate vision testing in pre-verbal and non-verbal patients is an unmet goal of pediatricians, family doctors, ophthalmologists, early education programs and parents who are interested in discovering vision programs in infants and children as early as possible in order to optimize vision outcomes. Unfortunately, only one-third of all children in the US have had a vision screening test or visual examination prior to entering school as existing early childhood screening devices detect only risk factors with high false-positive and false-negative rates.
Vifant’s vision acuity test app uses the established principle of optcokinetic nystagmus (OKN) which is the eyes’ reflexive, spontaneous response to moving patterns that does not need to be instructed or learned. The app is downloaded to a mobile tablet form and the tablet’s front-facing camera and screen provide stimulus and detection of eye movement to allow for identification of the eyes’ response to moving targets. The Vifant vision acuity test is patent protected and is reimbursable under the existing CPT code 99174. In addition to conventional points of service, Vifant’s mobility and ease of use fit well in a telemedicine strategy broadening the patient pool that will benefit from the test.
3 Major Issues
|
- Reimbursement challenges and opportunities: Does return on investment on early detection and intervention for a large number of patients outweigh costly treatments later from the payers perspectives and therefore warrant coverage in health plans? What is the role of consumers (parents, caretakers) as payers.
- Business model: Subscription fee per HCP or fee per test? Is there a play for remote result interpretation (telemedicine) right away or should it wait?
- Competitive landscape:What will be the competitors’ response to Vifant’s entry into the pediatric vision screening space.
Program:
|
6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)
8:00 - Beth DeSouza, CEO, will deliver the Company's "Elevator" Pitch to the Group
8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.
9:00 - Open discussion: members and guests
|
 |
 Slides
None available at this time
 Audio
None available at this time
 Video
None available at this time
 Webcast
Vifant Webcast - 11/ 9/15
|
|
|
